Skip to main content

Advertisement

Table 4 Change in total WOMAC score from baseline

From: Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Analytical method Type of analysis Time point (Days) Placebo (n = 53) GC (n = 57) UC-II (n = 54) p value (95 % CI)
Overalla GC vs PBO UC-II vs PBOb UC-II vs GC
ANCOVA mITT 180 −414 ± 28.5 −454 ± 27.5 −551 ± 28.2 0.002 0.56 (−134 to 53) 0.002 (−232 to −42) 0.04c (−190 to −3)
MMRM mITT 180 −397 ± 28.6 −452 ± 27.6 −514 ± 28.3 0.014 0.33 (−148 to 37) 0.0097 (−210 to −24) 0.25 (−153 to 30)
    (n = 58) (n = 65) (n = 63)     
iAUC ITT 1 to 180 −1479 ± 137 −1751 ± 130 −2042 ± 132 0.014 0.33 (−718 to 174) 0.0098 (−1012 to −113) 0.26 (−727 to 146)
  1. Values presented as Mean ± SE
  2. Abbreviations: PBO placebo
  3. aOverall p value was obtained by comparing the mean changes among the three groups using ANCOVA
  4. bSignificant difference between the UC-II and the placebo groups using Tukey-Kramer test
  5. cSignificant difference between the UC-II and the GC groups using Tukey-Kramer test